It is well known that SGLT2 inhibitors reduce proteinuria secondary to a degree that not only corrects hyperglycemia but also decreases the intraglomerular pressure by restoring the damaged tubuloglomerular feedback in the kidneys [26–28]. The gene discussed is SLC5A2; the disease is Hyperglycemia.